alpha-MSH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-04. Anything still debated is marked as such rather than presented as settled.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
==== Prontosan ==== Prontosan (B Braun) Wound Irrigation Solution and Prontosan Wound Gel are proprietary preparations of PHMB with betaine, an alkaloid surfactant. Surfactants lower the surface tension of the fluid medium making it easier to infiltrate wound coatings, debris and bacteria. Both the wound irrigation solution and the wound gel are colorless cleansing agents that are indicated for use in acute and chronic wounds. They also have the potential to be used in conjunction with a range of dressing materials which include occlusive dressings. In vitro studies on clinical isolates of E. coli and S. epidermidis have demonstrated the anti-biofilm efficacy of PHMB. The activity of five biocides at various concentrations was recorded following exposure to the isolates. The biocides found to be most active towards planktonic (free floating) cells were PHMB and peracetic acid. A corresponding level of activity towards biofilm phenotype bacteria was also found with the two agents. Prontosan's activity on MRSA biofilms has been investigated using an in vivo porcine wound model. Prontosan activity was compared with Ringer's solution, saline, and untreated control. A comparative reduction in MRSA at 48 and 72 hours in the Prontosan-treated group was found to be statistically significant compared to the other groups (p-value <0.05). The study results indicated that extended irrigation with Prontosan may provide additional reduction in wound bioburden as the largest reduction of MRSA was found from 48 to 72 hours.
== Achievements == Pultronics has contributed to the design flow of integrated circuits. Through the development of TED, an EDA thermal analysis tool of ICs, Pultronics provided an additional layer of verification to integrated circuit design. What makes TED different from other similar tools is that the thermal analysis is based on the physical topology of the IC instead of its schematic entry. Pultronics has also contributed to the testing of integrated circuits with the development of independent modules that could be placed directly on the IC. Such modules typically provide valuable information on the performance of the IC without resorting to complex measurement setups. Traditional methods of IC testing can require measurement equipment which are costly (>10-100k$) and can also distort the measured information.
==== I. Lipophilic Drugs ==== Microbubbles can facilitate the local targeting of hydrophobic drugs through the incorporation of these agents into the microbubble lipid shell. This encapsulation technique reduces systemic toxicity, increases drug localization, and improves the solubility of hydrophobic drugs. For increased localization, a targeting ligand can be appended to the exterior of the microbubble. This improves treatment efficacy. One drawback of the lipid-encapsulated microbubble as a drug delivery vehicle is its low payload efficacy. To combat this, an oil shell can be incorporated to the interior of the lipid monolayer to enhance payload efficacy.
Granulomatous inflammation: Characterised by the formation of granulomas, granulomatous inflammations result from a limited but diverse number of diseases, which include among others tuberculosis, leprosy, sarcoidosis, and syphilis. Fibrinous inflammation: Inflammation resulting in a large increase in vascular permeability allows fibrin to pass through the blood vessels. If an appropriate procoagulative stimulus is present, such as cancer cells, a fibrinous exudate is deposited. This is commonly seen in serous cavities, where the conversion of fibrinous exudate into a scar can occur between serous membranes, limiting their function. The deposit sometimes forms a pseudomembrane sheet. During inflammation of the intestine (pseudomembranous colitis), pseudomembranous tubes can be formed. Purulent inflammation: Inflammation resulting in a large amount of pus, which consists of neutrophils, dead cells, and fluid. Infection by pyogenic bacteria such as staphylococci is characteristic of this kind of inflammation. Large, localised collections of pus enclosed by surrounding tissues are called abscesses. Serous inflammation: Characterised by the copious effusion of non-viscous serous fluid, commonly produced by mesothelial cells of serous membranes, but may be derived from blood plasma. Skin blisters exemplify this pattern of inflammation. Ulcerative inflammation: Inflammation occurring near an epithelium can result in the necrotic loss of tissue from the surface, exposing lower layers. The subsequent excavation in the epithelium is known as an ulcer.
=== United States === The first country to have TPMS mandatory was the United States of America. In the early 2000s, numerous traffic accidents such as rollovers and tire blowouts occurred due to insufficient air pressure level. NHTSA regarded flat tires as a potential threat to safety which was soon followed by the enactment of Federal Motor Vehicle Safety Standard 138 on attaching TPMS for every vehicle by September 2007, phased in from 2005. The standard is to warn drivers of significant under-inflation of tires and the resulting safety problems of low tire pressure. This standard requires TPMS to be installed in all new passenger cars, multipurpose passenger vehicles, trucks, and buses that have a gross vehicle weight rating (GVWR) of 4,536 kg (10,000 lbs.) or less, except those vehicles with dual wheels on an axle. The final rule requires that the driver be given a warning when tire pressure is 25 percent or more below the vehicle manufacturer's recommended cold tire inflation pressure (placard pressure) for one to four tires.
Sources: en.wikipedia.org
Some of these cells (for example, LLC MK2, 4647 and HEK 293) do not express a protease that processes fusion protein F0 of Sendai virus; therefore, they produce non-infectious virions. Type 1 IFN inhibits the SeV production in normal human respiratory cells, but fails of doing it in human cells that originates from variable malignancies such as U937, Namalwa, and A549. Variable cell cultures obtained from tumors have different sensitivity to SeV, and can also produce the virus in different quantities. There are multiple factors that are responsible for this variability. For example, an inverse correlation was observed between cells sensitivity to SeV infection and constitutive mRNA expression levels of TLR 3 and TLR 7 in primary cultures of prostate cancer. Thus, defective TLR-activated IFN signaling is one of these factors.
Pathology informatics is a subfield of health informatics. It is the use of information technology in pathology. It encompasses pathology laboratory operations, data analysis, and the interpretation of pathology-related information. Key aspects of pathology informatics include:
Richardson and coworkers designed a 79-residue protein with no sequence homology to a known protein. In the 1990s, the advent of powerful computers, libraries of amino acid conformations, and force fields developed mainly for molecular dynamics simulations enabled the development of structure-based computational protein design tools. Following the development of these computational tools, great success has been achieved over the last 30 years in protein design. The first protein successfully designed completely de novo was done by Stephen Mayo and coworkers in 1997, and, shortly after, in 1999 Peter S. Kim and coworkers designed dimers, trimers, and tetramers of unnatural right-handed coiled coils. In 2003, David Baker's laboratory designed a full protein to a fold never seen before in nature. Later, in 2008, Baker's group computationally designed enzymes for two different reactions. In 2010, one of the most powerful broadly neutralizing antibodies was isolated from patient serum using a computationally designed protein probe. In 2024, Baker received one half of the Nobel Prize in Chemistry for his advancement of computational protein design, with the other half being shared by Demis Hassabis and John Jumper of Deepmind for protein structure prediction. Due to these and other successes (e.g., see examples below), protein design has become one of the most important tools available for protein engineering. There is great hope that the design of new proteins, small and large, will have uses in biomedicine and bioengineering.
=== Regulation of cell adhesion, migration, and survival === The α1β1 Integrin receptor binds collagens in the ECM and connects the α1β1 integrin complex to f-actin through the cytoplasmic tails of the integrin's recruitment of focal adhesion adaptor proteins (Talin, Kindlin, Paxillin, Vinculin, A-Actinin) which connects ECM to the actin cytoskeleton inside cells. This helps cells stick to and move throughout tissues. The interactions Integrin Alpha-1 has with the extracellular matrix promotes cell adhesion, migration, survival, and metastasis. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1 promotes tumor cell adhesion and migration on collagen substrates. Loss of ITGA1 reduces collagen-dependent attachment, spreading, and cellular viability, demonstrating that ITGA1 functions as a receptor linking ECM composition to cellular behavior. ITGA1 also supports survival of aggressive tumor cell populations. In PDAC, ITGA1 identifies ALDH1-high stem-like cancer cells and contributes to the maintenance and viability of tumor-initiating populations. Reduction of ITGA1 decreases survival of ALDH1-high cells, which suggests that ITGA1 regulates pathways involved in tumor cell persistence and stem-like properties.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.